Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research.
Daisuke TakahariEiji ShinozakiTakeru WakatsukiAkira OokiMasato OzakaTakeshi SuzukiIzuma NakayamaHiroki OsumiDaisaku KamiimabeppuTaro SatoMariko OguraMitsukuni SuenagaKeisho ChinKensei YamaguchiPublished in: International journal of clinical oncology (2020)
Coronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of emergency was declared in Japan, as had been by other nations worldwide. This unprecedented crisis has profound implications for patients undergoing chemotherapy and for practicing healthcare professionals. Various reports have shown data indicating that cancer patients with COVID-19 have high morbidity and mortality rates. In order to reduce the use of medical resources to avoid the risk of COVID-19 infections in both cancer patients and health care providers, oncologists now have to draw the line for cancer treatments by maintaining their efficacy while avoiding severe adverse events. In this article, we outlined the decisions made regarding the practice of gastrointestinal oncology in our institution during the COVID pandemic.
Keyphrases
- coronavirus disease
- healthcare
- papillary thyroid
- sars cov
- squamous cell
- patients undergoing
- primary care
- emergency department
- public health
- palliative care
- lymph node metastasis
- squamous cell carcinoma
- machine learning
- childhood cancer
- autism spectrum disorder
- intellectual disability
- deep learning
- adverse drug
- drug induced